Intellia Therapeutics. has filed a patent for compositions and methods to reduce HLA-A protein expression in cells for adoptive cell transfer therapies. The claim describes an engineered human cell with reduced HLA-A expression, genetically modified in the HLA-A gene, and homozygous for HLA-B and HLA-C. GlobalData’s report on Intellia Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intellia Therapeutics, CRISPR genome editing was a key innovation area identified from patents. Intellia Therapeutics's grant share as of January 2024 was 3%. Grant share is based on the ratio of number of grants to total number of patents.
Genetic modification to reduce hla-a protein expression in cells
See Also:
A recently filed patent (Publication Number: US20240024478A1) describes engineered human cells with reduced or eliminated surface expression of HLA-A, achieved through genetic modifications in the HLA-A gene. These modified cells are homozygous for HLA-B and HLA-C, and the genetic modifications target specific nucleotide sequences within the HLA-A gene. The patent claims cover various aspects of the engineered cells, including reduced or eliminated expression of specific HLA-A alleles, gene editing systems for reducing HLA-A expression, and methods for administering these engineered cells to treat diseases like cancer, infectious diseases, and autoimmune disorders.
Furthermore, the patent details methods for making these engineered cells, involving the use of HLA-A guide RNA and RNA-guided DNA binding agents like Cas9. The engineered cells can also be engineered with exogenous nucleic acids encoding targeting receptors or secreted polypeptides. Additionally, the patent covers the use of these engineered cells in pharmaceutical compositions and cell populations, with a focus on achieving high levels of HLA-A negativity. The patent also discusses the potential applications of these engineered cells in adoptive cell transfer therapy and the importance of matching HLA-B and HLA-C alleles between the engineered cells and recipient subjects for optimal therapeutic outcomes. Overall, the patent highlights the innovative genetic modifications and applications of engineered human cells with reduced HLA-A expression for various therapeutic purposes.
To know more about GlobalData’s detailed insights on Intellia Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
